Alzheimer’s Disease Is The Fastest Growing Health Threat To Americans

Alzheimer’s Disease Is The Fastest Growing Health Threat To Americans

Alzheimers Disease Is The Fastest Growing Health Threat To Americans
Anti-Alzheimer's, Antidimentia

A report issued from the University of Washington in Seattle on March 5, 2013 revealed a startling statistic. The fastest growing health threat to Americans is not cancer or heart disease – it is Alzheimers disease! While this may not have been surprising information to groups like the Alzheimer’s Association, who have been predicting an onslaught of future cases, many Americans were shocked by the report. The ever growing aging population in the United States has  certainly propelled this devastating disease into the spotlight. The report from the University of Washington offered both somber and scary predictions, projecting  that the number of patients Alzheimer ’s disease will  triple in the next 40 years, affecting an estimated13.8 million in the year 2050.

This latest information has given a new sense of urgency for finding a cure for Alzheimer ’s disease. There are several APIs  that are on the forefront of research and development, however. Donepezil, CAS number 120014-06-4, also known as the brand name Aricept, is an efficacious treatment for the symptoms of Alzheimer’s disease. Patients with Alzheimer’s have shown to have low levels of the brain chemical acetylcholine, which is a crucial chemical for thinking and memory issues. Donepezil improves the patient’s nerve cell functioning by inhibiting the breakdown of acetylcholine. Recent research regarding new drugs that are similar to donepezil was revealed at the Neuroscience Conference in South Australia on February 4, 2013. Bionomics Limited announced that new data on BNC375, its drug candidate with potential for the treatment of memory loss in Alzheimer’s Disease, would be explored as the next new Alzheimer’ drug. The performance of BNC375 in animal tests thus far matches donepezil results. BNC375, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor, has proven in a number of animal studies that it successfully enhances both episodic memory and working memory, and compares equivocally to the performance of donepezil {Aricept}.

Memantine, CAS number 41100-52-1, is another effective oral medication for treating patients with Alzheimer’s disease. Memantine is the first in a new and formidable class of Alzheimer’s drugs which work by blocking NMDA glutamate receptors. Known as its brand name Namenda, marketed in the United States by Forest Laboratories, memantine is typically prescribed for the treatment of moderate to severe dementia associated with Alzheimer’s disease. On March 7, 2012 a study was released and published in the New England Journal of Medicine, which involved 295 Alzheimer’s patients in Britain who were given memantine and donepezil. These patients were placed in one of four separate groups: patients continuing to take donepezil; patients stopping donepezil and receiving a placebo; patients stopping donepezil and starting memantine; and patients taking both memantine and donepezil together. The value of treating patients with mild to severe Alzheimer’s was found upon studying the effects of both memantine and donepezil. The continuation of drug treatment, even in patients deemed severe, proved to be effectual and successful when compared to the placebo group in this study. Patients who received both memantine and donepezil in this study fared significantly better, displaying worthier cognitive and functional abilities in comparison to the other study participants.

Bexarotene, CAS number 153559-49-0, has also been shown to be a potential opponent in the fight against Alzheimer’s disease. As of February 13th, 2012 Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation, announced documented success in studies using bexarotene. These studies demonstrated a distinct benefit to bexarotene in clearing out the excess plaque found in the Alzheimer’s-disease brains of the mice studied. Bexarotene also effectively enhanced  the body’s natural defense mechanisms, and helped to clear amyloid beta proteins, which is a naturally occurring protein in the brain that is unable to be cleared from the Alzheimer’s diseased brain.

LGM Pharma provides API bexarotene, as well as memantine and donepezil for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service